All In Biotech

Drug Trial Radar · NCT06268873

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

A Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,554 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,554

Actual

Start

Mar 29, 2024

Primary completion

Feb 24, 2028

Study completion Feb 24, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants untreated with SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin; and approximately 12-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone. Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 12-weeks (approximately), where reassessment of eGFR will occur for the primary efficacy endpoint. In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.

Conditions

  • Chronic Kidney Disease and Hypertension

Interventions

  • Baxdrostat/dapagliflozinDrug

    baxdrostat tablet dapagliflozin tablet

  • Dapagliflozin in combination with placeboDrug

    dapagliflozin tablet placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone to slow CKD progression, assessed as the effect on change in eGFR over time.Time frame: Baseline - 2 years + 12 weeks

Locations

565 sites in 38 countries. Site status is shown where the registry gives one.

  • Research Site

    Fairhope, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Surprise, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Searcy, Arkansas

  • Research Site

    Beverly Hills, California

  • Research Site

    Canyon Country, California

  • Research Site

    Fremont, California

  • Research Site

    Fullerton, California

  • Research Site

    Lincoln, California

  • Research Site

    Los Alamitos, California

  • Research Site

    San Francisco, California

  • Research Site

    Stanford, California

  • Research Site

    Tarzana, California

  • Research Site

    Arvada, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    New Britain, Connecticut

  • Research Site

    Boca Raton, Florida

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Edgewater, Florida

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jacksonville Beach, Florida

  • Research Site

    Lake City, Florida

  • Research Site

    Lake Worth, Florida

  • Research Site

    Melbourne, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    New Port Richey, Florida

  • Research Site

    Ocoee, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Riverview, Florida

  • Research Site

    Winter Haven, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Conyers, Georgia

Showing 40 of 565 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.